Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Randomized, Open-label Study to Evaluate the Potential Pharmacokinetic and Pharmacodynamic Interactions Between RDEA3170 and Allopurinol in Adult Male Subjects With Gout

NCT02279641 is registered in ClinicalTrials.gov with Ardea Biosciences, Inc. as lead sponsor.

NCT NCT02279641
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02279641 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Randomized, Open-label Study to Evaluate the Potential Pharmacokinetic and Pharmacodynamic Interactions Between RDEA3170 and Allopurinol in Adult Male Subjects With Gout
Lead sponsor
Ardea Biosciences, Inc.
Phase
Phase 1
Overall status
Completed
Start date
November 1, 2014
Completion date
September 11, 2015
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gout